Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 13/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | PNMT | P11086 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29668638 | 1.00 | SLC6A4 (0.49) | SLC6A4SLC6A2SLC6A3ALDH1A1TSHR | |
| Bromide SCHEMBL17910312 | 0.98 | SLC6A4 (0.47) | SLC6A4SLC6A2SLC6A3ALDH1A1TSHR | |
| SCHEMBL125255 | 0.87 | ALDH1A1 (0.57) | SLC6A4SLC6A2SLC6A3ALDH1A1TSHR | |
| SCHEMBL29729780 | 0.87 | ALDH1A1 (0.57) | SLC6A4SLC6A2SLC6A3ALDH1A1TSHR | |
| SCHEMBL30607608 | 0.85 | DPP4 (0.53) | SLC6A4SLC6A2SLC6A3ALDH1A1TSHR | |
| SCHEMBL29223182 | 0.81 | SLC6A4 (0.49) | SLC6A4SLC6A2SLC6A3ALDH1A1TSHR | |
| Methylamine SCHEMBL28339099 | 0.79 | PNMT (0.57) | SLC6A4SLC6A2SLC6A3PNMTHTR2A | |
| SCHEMBL29405036 | 0.79 | PNMT (0.63) | PNMTKDM4ESMN1; SMN2 | |
| SCHEMBL15247 | 0.79 | PNMT (0.63) | PNMTKDM4ESMN1; SMN2 | |
| SCHEMBL20237930 | 0.79 | PNMT (0.39) | SLC6A4SLC6A2SLC6A3PNMTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3628045-B1 | COMPOUNDS | UNIV SHEFFIELD (GB) | 2024-07-03 | — | — | EP | disclosed |
| CN-114310656-B | Polishing pad, method for manufacturing polishing pad, and method for manufacturing semiconductor device | SK恩普士有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20230286917-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230165833-A1 | Selective Butyrylcholinesterase Inhibitor or Pharmaceutically Acceptable Salt Thereof, Preparation Method and Use Thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2023-06-01 | — | — | US | disclosed |
| US-11639333-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC (US) | 2023-05-02 | — | — | US | disclosed |
| US-11214542-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-11-16 | — | — | US | disclosed |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-11-16 | — | — | US | disclosed |
| US-20210171537-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2021-06-10 | — | — | US | disclosed |
| US-20210171537-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2021-06-10 | — | — | US | disclosed |
| US-20150119397-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-30 | — | — | US | disclosed |
| US-8952151-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140213591-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-07-31 | — | — | US | disclosed |
| WO-2014100818-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2008138595-A1 | ELASTIC FIBER | DSM IP ASSETS B.V. (NL) | 2008-11-20 | — | — | WO | disclosed |
| CN-1655058-A | Photosensitive transfer sheet | FUJI PHOTO FILM CO LTD (JP) | 2005-08-17 | — | — | CN | disclosed |
| EP-1143991-A2 | INHIBITORS OF H+K+ -ATPASE | Advanced Medicine, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-1999063940-A2 | INHIBITORS OF H+K+-ATPase | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| US-4253886-A | Corrosion resistant ferromagnetic metal powders and method of preparing the same | FUJI PHOTO FILM CO., LTD. (JP) | 1981-03-03 | — | — | US | disclosed |
| US-4137217-A | QUARTERNARY AMMONIUM POLYAMINE-POLYCARBOXYLIC ACID | Tsuchida, Eishun (JP) | 1979-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11214542-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | SLC6A4 4493/4885SLC6A2 4516/4885SLC6A3 4472/4885 |
| US-20230286917-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | SLC6A4 4493/4885SLC6A2 4516/4885SLC6A3 4472/4885 |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | KCND2, SCN1A, CACNA1D | SLC6A4 147/4885SLC6A2 144/4885SLC6A3 222/4885 |
| US-20230165833-A1 | Selective Butyrylcholinesterase Inhibitor or Pharmaceutically Acceptable Salt Thereof, Preparation Method and Use Thereof | BCHE, ACHE, BACE1 | SLC6A4 86/4885SLC6A2 9/4885SLC6A3 60/4885 |
| US-11639333-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | SLC6A4 4493/4885SLC6A2 4516/4885SLC6A3 4472/4885 |
| US-20210171537-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | SLC6A4 175/4885SLC6A2 149/4885SLC6A3 186/4885 |
| US-20150119397-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | SLC6A4 4493/4885SLC6A2 4516/4885SLC6A3 4472/4885 |
| US-20140213591-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | SLC6A4 4493/4885SLC6A2 4516/4885SLC6A3 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.